Briacell Therapeutics Corp BCTX

$3.46 +0.08 (2.37%)

Valuation

Market cap
29,579,000
Revenue TTM
$0
Net income TTM
$-26,310,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
35,481
Avg volume
313,968
Day's range
$3.36 – $3.59
Shares out
8,700,000
Stochastic %K
0%
Beta
1.21
Analysts
Strong Buy
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 921 1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news

Stocktwits

BCTX20bMC Oct 20, 5:25 PM
$BCTX Moderna is now a 96b co…..after positive P3 data…never sell your shares.
0 replies
Biotechlineup Oct 20, 4:15 PM
$BCTX The 2026 Citeline Awards (also highlighting the inaugural Citeline Biotech Awards) will take place on Thursday, November 12, 2026, at the InterContinental Boston in Boston, Massachusetts. This premier event gathers influential leaders from the biopharmaceutical, contract research organization (CRO), and diagnostics sectors to celebrate the most groundbreaking advancements and trailblazers in clinical R&D https://citeline.com/awards/citelineawards/?elqTrackId=FA12266C83973518B37544E63EE1CB46&elqaid=4419&elqat=2&elqak=8AF555B0F6D893525C44C2BA09B23299F3EE0C7040B46A003699AAFD6A99A8BC1946
0 replies
smallpower17 Oct 20, 3:10 PM
$BCTX I'm guessing around end of November / start of December 2026 for Phase 3 readout.
1 replies
SmallCapVoice Oct 20, 12:14 PM
BriaCell Therapeutics ($BCTX) is featured in Prism MarketView’s coverage of emerging biotechs targeting metastatic breast cancer. Read the feature and explore BriaCell’s other media coverage here: https://briacell.com/media-coverage/
0 replies
Manwiththeplan Oct 19, 5:59 PM
$BCTX William V. Williams, M.D., F.A.C.P., President and CEO, BriaCell Therapeutics Corp. | Big4Bio https://share.google/87B3dzXvdPC7foRdJ
1 replies
CoffeeRocks Oct 19, 3:02 PM
$TCRT $SLS $BCTX $LPCN $CAPR TCRT trades like it’s about to do an ATM offering
0 replies
SmallCapVoice Oct 19, 11:45 AM
BriaCell ($BCTX) is in the spotlight on FintechTvGlobal as Dr. William Williams discusses its pivotal Phase 3 breast cancer trial, the path toward headline data, and clinical findings that could shape future treatment options for patients with metastatic breast cancer. Watch the interview: https://terminal.fintech.tv/fintechtv-library/episode/briacells-phase-three-trial-could-change-late-stage-breast-cancer-treatment
1 replies
JediGreen Oct 19, 4:57 AM
$BCTX https://youtu.be/5degIsw-fTI
0 replies